NCT07326709ClinicalTrials.gov
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
A Randomized, Placebo-controlled, Double-blind Phase 3 Study to Evaluate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
En bref
The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm. HTT227 - current compound code (former code is PTC518…
Phase 3770 participants recherchés117 sites27 pays
Catégories
Enregistré dans 1 registre
- ClinicalTrials.govNCT07326709Ouvrir cette fiche sur ClinicalTrials.govSynchronisé il y a 2 mois
Une même étude peut être enregistrée dans plusieurs registres. Nous l'affichons une seule fois et renvoyons vers chaque fiche que nous détenons.
Les informations de l'essai sont affichées telles que publiées par le registre, dans leur langue d'origine.
Cette étude vous intéresse ?
Se connecter ou créez un compte pour manifester votre intérêt et suivre cette étude.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2026-01-08; recorded start 2026-03-24
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 1147 other studies in this databaseCounted from the lead sponsor named in the record (Novartis Pharmaceuticals)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm13/15
Placebo / sham control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 41 sites
- Data monitoring committee7/7
A data monitoring committee is in place
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A medium-sized study, international in scope: 770 participants (target), run at 117 sites, across 27 countries.
How this score is built
- Enrolment28/40
770 participants (target)
- Site count19/25
41 sites
- Country count12/15
9 countries
- Planned duration9/10
Planned over about 50 months
- Sponsor scale10/10
Novartis Pharmaceuticals has led 1,104 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Résumé
The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm. HTT227 - current compound code (former code is PTC518 from PTC Therapeutics), HTT227 is Novartis code under Novartis sponsorship.
Affections
- Huntington Disease
Éligibilité
| Sexe | Tous |
|---|---|
| Âges | 21 Years – 70 Years |
| Volontaires sains | Non |
Éligibilité telle qu'elle figure dans le registre
Éligibilité en énoncés simples
Les critères de cette fiche n'ont pas encore été décomposés en énoncés distincts. Le texte du registre ci-dessus est complet et fait foi.
Conception de l'étude
| Type d'étude | Interventionnelle |
|---|---|
| Phase | Phase 3 |
| Répartition | Randomisée |
| Modèle d'intervention | PARALLEL |
| Objectif principal | TREATMENT |
| Insu | QUADRUPLE (4) |
| Recrutement | 770 participants recherchés |
Promoteur et collaborateurs
- Novartis Pharmaceuticals Promoteur
Groupes et interventions
- VotoplamEXPERIMENTAL
Votoplam (blinded) taken orally, randomized in a 3:2 ratio (Votoplam: Placebo)
- PlaceboPLACEBO_COMPARATOR
Placebo (blinded) taken orally, randomized in a 3:2 ratio (Votoplam: Placebo)
Interventions
- Médicament Placebo
Placebo
- Médicament Votoplam (blinded)
Votoplam (blinded) active treatment
Critères de jugement
Critère de jugement principal
Change from Baseline in cUHDRS score
The Composite Unified Huntingtons Disease Ratings Scale (cUHDRS) is an improved composite measure to assess multi-domain clinical progression in HD. The cUHDRS is a combined weighted score of measures of motor function (TMS), cognition (SDMT and SWRT) and overall functional capacity (TFC): cUHDRS = \[(TFC-10.4)/1.9 - (TMS-29.7)/14.9 + (SDMT-28.4)/11.3 + (SWRT - 66.1)/20.1\] + 10. In conjunction with one another, these measures provide a comprehensive, sensitive and specific tool for monitoring disease progression, with lower scores indicating more severe disease. cUHDRS score range from -8 to 25.
Délai Baseline, Month 36
Critère de jugement secondaire
Change from Baseline in UHDRS-TFC
The UHDRS-Total Functional Capacity (TFC) focuses on the Investigator's assessment of the participant's capacity to perform a range of activities including occupation, finances, self-care, domestic chores and activities of daily living. The responses are derived from interview with the participant and/or companion, if applicable. Scores range from 0 to 13, with higher scores representing better functioning.
Délai Baseline, Month 36
Critère de jugement secondaire
Change from Baseline in UHDRS-IS
The UHDRS-Independence Scale (IS) measures a patient's overall level of functional independence in activities of daily living. It provides a single score ranging from 10 (total dependence/bedbound) to 100 (no special care needed) in intervals of 10, with higher scores indicating better functioning. Scores can also be assigned in increments of 5 for intermediate levels of function.
Délai Baseline, Month 36
Critère de jugement secondaire
The time to decline in TFC score by at least one or IS score by at least 10
The UHDRS-Total Functional Capacity (TFC) focuses on the Investigator's assessment of the participant's capacity to perform a range of activities including occupation, finances, self-care, domestic chores and activities of daily living. The responses are derived from interview with the participant and/or companion, if applicable. Scores range from 0 to 13, with higher scores representing better functioning. The UHDRS-Independence Scale (IS) measures a patient's overall level of functional independence in activities of daily living. It provides a single score ranging from 10 (total dependence/bedbound) to 100 (no special care needed) in intervals of 10, with higher scores indicating better functioning. Scores can also be assigned in increments of 5 for intermediate levels of function.
Délai Baseline to end of treatment up to 36 months
Critère de jugement secondaire
Change from Baseline in UHDRS-TMS
The UHDRS-Total Motor Score (TMS) is the cumulative sum of the individual motor ratings obtained during the administration of the motor assessment portion of the UHDRS. It includes items related to eye movements, speech, limb movements (including hand taps and pronation-supination), dystonia, chorea, and gait/balance. Scores range from 0 to 124, with higher scores indicating greater motor impairment.
Délai Baseline, Month 36
Critère de jugement secondaire
Change from Baseline in SDMT
The Symbol Digit Modality Test (SDMT) is used to assess attention, working memory, psychomotor speed and visual perceptual processing. Participants are presented with a translation key of specific numbers paired with unique abstract symbols. Below the translation key is an array of symbols paired with empty spaces, the participant's task is to match the number for each symbol as quickly as possible in a given time frame. Scores are based on number of correctly paired items and range from 0 to 110, with higher scores representing better performance.
Délai Baseline, Month 36
Critère de jugement secondaire
Change from Baseline in SWRT
The Stroop Word Reading Test (SWRT) is a measure of processing and psychomotor speed. Participants are presented with a list or words (color names) printed in black ink and asked to read aloud as many words as possible within a set timeframe. Scores are based on the number of words read correctly and range from 0 to 60, with higher scores representing better performance.
Délai Baseline, Month 36
Critère de jugement secondaire
Percent change from Baseline in blood mHTT protein
The mutant huntington protein (mHTT) which is detectable both in blood and cerebrospinal fluid (CSF), represents a reliable biomarker for HD due to its direct involvement in disease pathology. Blood mHTT is a direct product of the pathogenic HTT gene mutation and represents a proximal marker of Huntington's disease (HD) biology.
Délai Baseline to steady state and up to 36 months in blood mHTT protein
Critère de jugement secondaire
Change from Baseline in serum NfL
Serum Neurofilament light chain NfL is a component of the neuronal cytoskeleton, released into CSF and blood after neuro-axonal damage, serving as a marker of neurodegeneration and disease progression in HD.
Délai Baseline, Month 36
Critère de jugement secondaire
Incidence and severity of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) and TEAEs leading to participant withdrawal
Number of participants with AEs and SAEs, including notable findings on physical examination, changes in vital signs, laboratory parameters, ECG, etc.
Délai Baseline to up to 36 months
Dates
| Date de début | 24 mars 2026 (réelle) |
|---|---|
| Achèvement principal | 2 avril 2030 (estimée) |
| Achèvement | 30 avril 2030 (estimée) |
| Première publication | 8 janvier 2026 (réelle) |
| Dernière mise à jour | 22 septembre 2026 |
| Résultats publiés | Non précisé dans la fiche du registre |
| Statut vérifié pour la dernière fois | septembre 2026 |
Réelle signifie que l'événement a eu lieu. Estimée signifie que le promoteur s'y attend. Les deux ont un sens différent.
Lieux
117 sites sont en recrutement
Argentina
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Novartis Investigative Site | Buenos Aires | En recrutement | |
| Instituto Argentino de Investigación Neurológica (IADIN) | CABA | Buenos Aires | En recrutement |
| Centro de Investigaciones Metabólicas (CINME) | CABA | Buenos Aires | En recrutement |
| Novartis Investigative Site | Ciudad de | Buenos Aires | En recrutement |
Australia
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Novartis Investigative Site | Caulfield South | Victoria | En recrutement |
| Novartis Investigative Site | Westmead | New South Wales | En recrutement |
Belgium
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Novartis Investigative Site | Leuven | Vlaams Brabant | En recrutement |
Bulgaria
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Novartis Investigative Site | Sofia | En recrutement | |
| Novartis Investigative Site | Sofia | En recrutement |
Canada
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| CUSM Montreal Neurological Institute | Montreal | Quebec | En recrutement |
| Centre de recherche du CHUM | Montreal | Quebec | En recrutement |
| North York General Hospital | North York | Ontario | En recrutement |
China
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Novartis Investigative Site | Beijing | En recrutement | |
| Novartis Investigative Site | Beijing | En recrutement | |
| The Second Xiangya Hospital of Central South University | Changsha | Hunan | En recrutement |
| West China Hospital of Sichuan Uni | Chengdu | Sichuan | En recrutement |
| Novartis Investigative Site | Fuzhou | Fujian | En recrutement |
| Novartis Investigative Site | Guangzhou | Guangdong | En recrutement |
| Novartis Investigative Site | Guangzhou | Guangdong | En recrutement |
| The Second Affiliated Hosp Of Zhejiang Univ School Of Medicine | Hangzhou | Zhejiang | En recrutement |
| Novartis Investigative Site | Shanghai | En recrutement | |
| Tongji Hos Affiliated Tongji Medical College of Huazhong | Wuhan | Hubei | En recrutement |
Colombia
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Novartis Investigative Site | Medellín | En recrutement |
Czechia
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Novartis Investigative Site | Brno | En recrutement | |
| Novartis Investigative Site | Prague | En recrutement |
Denmark
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Novartis Investigative Site | Copenhagen | En recrutement |
France
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Novartis Investigative Site | Angers | France | En recrutement |
| Novartis Investigative Site | Marseille | En recrutement | |
| Novartis Investigative Site | Montpellier | En recrutement |
Germany
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Novartis Investigative Site | Aachen | En recrutement | |
| Novartis Investigative Site | Bochum | En recrutement | |
| Novartis Investigative Site | Münster | En recrutement | |
| Novartis Investigative Site | Tübingen | En recrutement | |
| Novartis Investigative Site | Ulm | En recrutement |
Hungary
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Novartis Investigative Site | Budapest | En recrutement | |
| Novartis Investigative Site | Szeged | En recrutement |
Israel
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Tel Aviv Sourasky Med Ctr Ichilov | Tel Aviv | En recrutement |
Italy
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Novartis Investigative Site | Bologna | BO | En recrutement |
| Novartis Investigative Site | Brescia | BS | En recrutement |
| Novartis Investigative Site | Milan | MI | En recrutement |
| Novartis Investigative Site | Milan | MI | En recrutement |
Japan
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Novartis Investigative Site | Bunkyo Ku | Tokyo | En recrutement |
| Novartis Investigative Site | Kashihara | Nara | En recrutement |
| Novartis Investigative Site | Sagamihara | Kanagawa | En recrutement |
Netherlands
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Novartis Investigative Site | Leiden | South Holland | En recrutement |
| Novartis Investigative Site | Maastricht | Limburg | En recrutement |
Poland
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Novartis Investigative Site | Krakow | POL | En recrutement |
Portugal
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Novartis Investigative Site | Lisbon | En recrutement | |
| Novartis Investigative Site | Porto | En recrutement |
Romania
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Novartis Investigative Site | Bucharest | En recrutement |
67 sites supplémentaires sont indiqués dans la fiche du registre.
Documents de l'étude
Aucun document n'est lié dans cette fiche du registre.
Évolution au fil du temps
- 22 septembre 2026
Site ajouté
35 sites added (117 total)
82117
- 31 août 2026
Site ajouté
22 sites added (82 total)
6082
- 11 août 2026
Site ajouté
9 sites added (60 total)
5160
- 29 juillet 2026
Site ajouté
10 sites added (51 total)
4151